The process is using digital automation to more accurately guide the process with treating blocked arteries, and is integrated with other technologies from other companies.  Cardiology with all the new processes and software available today is getting pretty deep, as far as understanding what is being done and why. 

This process will also stand to reduce the amount of x-ray exposure as well.  As always, the key is is in the software that makes all this possible.  Healthcare is all about good software today.  BD 

ST. LOUIS, Aug 27, 2008 /PRNewswire-FirstCall via COMTEX/ -- Stereotaxis, Inc., announced today that it has received regulatory clearance from the U.S. Food and Drug Administration for its magnetically tipped, PowerAssert(TM) radiofrequency (RF) guidewire to cross chronic total occlusions in the peripheral vasculature.

Occluded or blocked arteries occur in patients with advanced peripheral arterial disease (PAD), and if left untreated can result in ulcerations and gangrene as well as significantly increased risk of limb loss and death.


"Through our alliances with Siemens, Philips and Biosense Webster, Inc., a Johnson & Johnson company, this precise digital instrument control has been integrated with the imaging and information systems used during interventional cardiology and electrophysiology procedures in order to provide the physician with a fully-integrated and automated information and instrument control system."

FDA Clears Stereotaxis Magnetic Radio Frequency Guidewire for Peripheral Chronic Total Occlusions - MarketWatch


Post a Comment

Google Analytics Alternative